TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11943102

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 1911

Group type: COMPARATOR
Intervention: Control treatment (no effect on H. pylori infection)
Number of subjects: 1911
Study: 9649995

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.9 mg kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium (0.12 mg kg‐1)
Number of subjects: 30
Study: 8543493

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 h (n = 77)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cefotaxime 2 g and metronidazole 500 mg every 8 h (n = 83)
Number of subjects: 160
Study: 2382949

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 30
Study: 6797288

Group type: EXPERIMENTAL
Intervention: Naso‐jejunal feedings (group I)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Total parenteral nutrition (group II)
Number of subjects: 17
Study: 31922355

Group type: EXPERIMENTAL
Intervention: Admission risk index (RI)
Number of subjects: 0
Study: 31039754

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of an individually tailored, progressive home exercise program and physical activity promotion delivered by professional instructors and lay instructors (two home visits per week) and long-term care counselling
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 240
Study: 29153415

Group type: EXPERIMENTAL
Intervention: Formoterol (FOM) DPI (9 μg via a Turbuhaler®)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tiotropium bromide (TIO) DPI (18μg via a HandiHaler®)
Number of subjects: 52
Study: 25986615

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1×10^8 CFU for five days) + Oral Rehydration Solution (ORS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (ORS only)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 + ORS
Number of subjects: 64
Study: 23166147

Group type: EXPERIMENTAL
Intervention: Remifentanil-based anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl-based anaesthesia
Number of subjects: 100
Study: 21739290

Group type: EXPERIMENTAL
Intervention: Relationship-based HIV sexual risk reduction intervention
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Relationship-based HIV sexual risk reduction intervention plus motivational interviewing
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control condition focused on wellness promotion
Number of subjects: 166
Study: 18754021

Group type: EXPERIMENTAL
Intervention: 24-h blood pressure management strategy (target <130/80 mm Hg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard strategy using office BP (target <140/90 mm Hg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 24-h blood pressure management strategy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard strategy using office BP
Number of subjects: 136
Study: 16998260

Group type: EXPERIMENTAL
Intervention: PercuSurge GuardWire System
Number of subjects: 58

Group type: COMPARATOR
Intervention: No distal protection device
Number of subjects: 58
Study: 15769682

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 732

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: OPCAB patients with moderate LVD
Number of subjects: 732

Group type: COMPARATOR
Intervention: CABG and OPCAB patients with severe LVD
Number of subjects: 732
Study: 10953942

Group type: EXPERIMENTAL
Intervention: Conflict resolution training integrated into a curriculum unit on friendship (9 hr over 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition (identical friendship unit without conflict resolution training)
Number of subjects: 80
Study: 1818806

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gamma-OH
Number of subjects: 60
Study: 6651994

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 585

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Not applicable (subsample of 171 patients)
Number of subjects: 585
Study: 29941406

Group type: EXPERIMENTAL
Intervention: Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dolutegravir plus abacavir and lamivudine
Number of subjects: 0
Study: 27262254

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study: 24752322

Group type: EXPERIMENTAL
Intervention: PVC group (propofol infusion via a 1‐m PVC infusion extension tube)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (propofol injected directly through the port of the cannula)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PVC group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group D (di(2‐ethylhexyl) phthalate added to samples)
Number of subjects: 100
Study: 22261236

Group type: EXPERIMENTAL
Intervention: Four treatment regimens for NGU
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Higher levels of education
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Clinical centers with higher monetary incentives
Number of subjects: 305
Study: 19874436

Group type: COMPARATOR
Intervention: Device eligibility based on MADIT-II criteria
Number of subjects: 4977

Group type: COMPARATOR
Intervention: Device eligibility based on CARE-HF criteria
Number of subjects: 4977

Group type: COMPARATOR
Intervention: Device eligibility based on SCD-HeFT criteria
Number of subjects: 4977

Group type: EXPERIMENTAL
Intervention: Registry patients with different trial-profile combinations
Number of subjects: 4977
Study: 18506317

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg), plus dexmedetomidine, 1 mg x kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (n = 20), 0.75% ropivacaine, 20 ml (150 mg)
Number of subjects: 40
Study: 16020438

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 39
Study: 12356613

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation with or without heat
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation with or without electrical muscle stimulation
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Cervical spine mobilization with or without heat
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Cervical spine mobilization with or without electrical muscle stimulation
Number of subjects: 336
Study: 10474015

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 19
Study: 8757002

Group type: EXPERIMENTAL
Intervention: Linomide (2.5 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1839061

Group type: EXPERIMENTAL
Intervention: Whole-ground sorghum cereal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Decorticated sorghum cereal
Number of subjects: 10
Study: 6148905

Group type: EXPERIMENTAL
Intervention: Org NC 45 during neurolept anaesthesia
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Org NC 45 during enflurane anaesthesia
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Org NC 45 during halothane anaesthesia
Number of subjects: 3
Study: 31392528

Group type: EXPERIMENTAL
Intervention: Age > 56 years and no lymphovascular invasion (LVI)
Number of subjects: 12918

Group type: EXPERIMENTAL
Intervention: Elderly patients (age > 75 years) with melanoma 1.2 mm or smaller and no LVI
Number of subjects: 12918
Study: 29478794

Group type: EXPERIMENTAL
Intervention: Rapid test from finger-stick whole blood
Number of subjects: 270

Group type: COMPARATOR
Intervention: ELISA tests
Number of subjects: 270
Study: 27614896

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23617228

Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH)
Number of subjects: 310
Study: 23402957

Group type: EXPERIMENTAL
Intervention: Rotation with Extension subgroup
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (without low back pain)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 21409494

Group type: EXPERIMENTAL
Intervention: Conivaptan (20 mg single dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study: 18079302

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 40
Study: 16782422

Group type: EXPERIMENTAL
Intervention: Calcium (750 mg), Vitamin K1 (1.0 mg), Vitamin D3 (10.0 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14668280

Group type: EXPERIMENTAL
Intervention: High-bioavailability diet (13.1 mg/d nonheme iron, 2.0 mg/d heme iron)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-bioavailability diet (14.8 mg/d nonheme iron, 0.3 mg/d heme iron)
Number of subjects: 0
Study: 10751219

Group type: EXPERIMENTAL
Intervention: 550 meq NaCl/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 200 meq NaCl/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 400 meq NaCl/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 50 meq NaCl/day
Number of subjects: 32
Study: 8667198

Group type: EXPERIMENTAL
Intervention: Octreotide (50 microgram)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1813974

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo (de novo patients)
Number of subjects: 0
Study: 6410589

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30952795

Group type: EXPERIMENTAL
Intervention: PSI-dTMS
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: ACC-dTMS
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham-dTMS
Number of subjects: 98
Study: 29743090

Group type: COMPARATOR
Intervention: Standard Provider Training Only
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Standard Provider Training + Leader Training
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Enhanced Provider Training
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Enhanced Provider Training + Leader Training
Number of subjects: 590
Study: 25615706

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - participated in a physical conditioning program throughout pregnancy, 55‐ to 60‐minute sessions, 3 days per week
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control Group (CG) - no specific intervention mentioned
Number of subjects: 166
Study: 24402391

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program featuring aerobic, strength, balance, and flexibility training
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program
Number of subjects: 177

Group type: COMPARATOR
Intervention: Successful Aging (SA) educational program
Number of subjects: 177
Study: 21920484

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiofrequency (RF) energy
Number of subjects: 60
Study: 20943877

Group type: EXPERIMENTAL
Intervention: V710 30 μg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: V710 90 μg
Number of subjects: 124

Group type: COMPARATOR
Intervention: V710 5 μg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 124
Study: 17559843

Group type: EXPERIMENTAL
Intervention: Injection of embryo culture supernatant (ECS)
Number of subjects: 48
Study: 15880336

Group type: EXPERIMENTAL
Intervention: VEGF +405 CC genotype
Number of subjects: 596

Group type: COMPARATOR
Intervention: VEGF +405 GG genotype
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: VEGF -460 polymorphism
Number of subjects: 596
Study: 12352783

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9578996

Group type: EXPERIMENTAL
Intervention: Early childhood education
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Head Start
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Public school preschool education
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-quality child care programs
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis from a randomized trial
Number of subjects: 38
Study: 8934727

Group type: EXPERIMENTAL
Intervention: FAC regimen (5‐FU 600 mg/m2 i.v. over 1 hour, DOX 50 mg/m2 i.v. bolus, CPM 400 mg/m2 i.v. bolus)
Number of subjects: 258

Group type: COMPARATOR
Intervention: FULON regimen (5‐FU 250 mg/m2 per day continuously infused, CPM 300 mg/m2 i.v. bolus, DOX 15 mg/m2 i.v. bolus)
Number of subjects: 258
Study: 2693027

Group type: EXPERIMENTAL
Intervention: Gangliosides (100 mg daily, 5 days per week for 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 690219

Group type: EXPERIMENTAL
Intervention: Assertion training group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Insight therapy group
Number of subjects: 80
Study: 31521754

Group type: EXPERIMENTAL
Intervention: Low-dose, Early Fresh Frozen Plasma Transfusion (LEFT) therapy (5 mL/kg body weight)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal saline (NO LEFT group) (5 mL/kg body weight)
Number of subjects: 63
Study: 28514264

Group type: EXPERIMENTAL
Intervention: 2‐min MOD walking (21 × 2 min bouts at 53% ± 5% HRmax)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2‐min VIG walking (8 × 2 min bouts at 79% ± 4% HRmax)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30‐min MOD walking (30 min at 71% ± 4% HRmax)
Number of subjects: 10

Group type: COMPARATOR
Intervention: SIT (9 h of prolonged sitting)
Number of subjects: 10
Study: 25724881

Group type: EXPERIMENTAL
Intervention: HydroSoft/HydroFrame coils
Number of subjects: 0

Group type: COMPARATOR
Intervention: bare platinum coils
Number of subjects: 0
Study: 23556410

Group type: EXPERIMENTAL
Intervention: Airtraq™, A. P. Advance™, King Vision™ (video-laryngoscopes with guiding channel)
Number of subjects: 720

Group type: COMPARATOR
Intervention: C‐MAC™, GlideScope™, McGrath™ (video-laryngoscopes without integrated tracheal tube guidance)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: All devices used in the trial
Number of subjects: 720
Study: 21677600

Group type: EXPERIMENTAL
Intervention: everolimus + reduced calcineurin inhibitor (CNI)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: everolimus + reduced CNI
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: AZA + everolimus
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: MMF + everolimus
Number of subjects: 111

Group type: COMPARATOR
Intervention: standard CNI
Number of subjects: 111
Study: 18405405

Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1 per cent nasal spray
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1 per cent nasal spray (in septoplasty patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Physiological saline aerosol
Number of subjects: 120
Study: 16380823

Group type: EXPERIMENTAL
Intervention: Intraoperative Trasylol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass without Trasylol
Number of subjects: 40
Study: 14672874

Group type: EXPERIMENTAL
Intervention: Intact seeds
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ground seeds
Number of subjects: 12
Study: 10759674

Group type: EXPERIMENTAL
Intervention: Snodgrass procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mathieu repair
Number of subjects: 60
Study: 8885583

Group type: EXPERIMENTAL
Intervention: Traditional research designs in pediatric psychopharmacology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative research designs in pediatric psychopharmacology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical research hypothesis evolution to study protocol
Number of subjects: 0
Study: 1397215

Group type: EXPERIMENTAL
Intervention: Breast Self-Examination (BSE) training
Number of subjects: 120310

Group type: COMPARATOR
Intervention: Control group (no BSE training)
Number of subjects: 120310

Group type: EXPERIMENTAL
Intervention: BSE group
Number of subjects: 120310

Group type: EXPERIMENTAL
Intervention: BSE group and Control group
Number of subjects: 120310
Study: 2858711

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 0.75 mg/kg over 90 min
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intravenous streptokinase at a dosage of 1,500,000 IU over 60 min
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both rt-PA and streptokinase
Number of subjects: 129
Study: 30141364

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.025% otic solution, administered twice daily for 7 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo otic solution, administered twice daily for 7 days
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.025% otic solution
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo otic solution
Number of subjects: 135
Study: 26358163

Group type: EXPERIMENTAL
Intervention: Buns with 10% fenugreek seed powder
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flatbreads with 10% fenugreek seed powder
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buns with 0% fenugreek seed powder (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flatbreads with 0% fenugreek seed powder (control)
Number of subjects: 10
Study: 24668360

Group type: EXPERIMENTAL
Intervention: Body awareness therapy (group sessions once a week for eight weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual daily activities (control group)
Number of subjects: 46
Study: 22425702

Group type: EXPERIMENTAL
Intervention: SCY‐635 900 mg/d
Number of subjects: 20
Study: 20223877

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 40
Study: 18314182

Group type: EXPERIMENTAL
Intervention: IFN‐gamma 1b plus carboplatin/paclitaxel
Number of subjects: 847

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel alone
Number of subjects: 847
Study: 15527149

Group type: EXPERIMENTAL
Intervention: Tartu population
Number of subjects: 805

Group type: COMPARATOR
Intervention: Uppsala population
Number of subjects: 805
Study: 11513186

Group type: EXPERIMENTAL
Intervention: i.v. glycyrrhizin treatment three times per week for 4 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: i.v. glycyrrhizin treatment six times per week for 4 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 9261640

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 47
Study: 8427942

Group type: EXPERIMENTAL
Intervention: Hymecromone 400 mg infused i.v. over 3 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hymecromone 800 mg infused i.v. over 5 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of hymecromone
Number of subjects: 6
Study: 3325721

Group type: EXPERIMENTAL
Intervention: Mechanical stapling (EEA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual single layer suturing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 28597614

Group type: EXPERIMENTAL
Intervention: Hang-clean training program (HCL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Half-squat training program (HSQ)
Number of subjects: 58
Study: 27810312

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1201

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1201
Study: 25015747

Group type: EXPERIMENTAL
Intervention: L-carnitine 3g daily plus 250 mg clomiphene citrate
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo plus 250 mg clomiphene citrate
Number of subjects: 170
Study: 20884658

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg twice daily
Number of subjects: 2052

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2052
Study: 20196678

Group type: EXPERIMENTAL
Intervention: Video Doctor plus provider cueing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 18672767

Group type: EXPERIMENTAL
Intervention: HAT combined with QHQ
Number of subjects: 81

Group type: COMPARATOR
Intervention: HAT alone
Number of subjects: 81
Study: 16823584

Group type: EXPERIMENTAL
Intervention: (S)-verapamil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (R)-verapamil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: racemic verapamil
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 12791633

Group type: EXPERIMENTAL
Intervention: Highest quartile of protein intake (72 g/d)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 489
Study: 11053706

Group type: EXPERIMENTAL
Intervention: Patients with chronic AF
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 22
Study: 8805893

Group type: EXPERIMENTAL
Intervention: Caudal epidural blockade
Number of subjects: 50

Group type: COMPARATOR
Intervention: Penile ring block
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study: 1628051

Group type: EXPERIMENTAL
Intervention: Accelerated immunisation schedule (2, 3, and 4 months of age)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard immunisation schedule (3, 4 1/2 to 5, and 8 1/2 to 11 months of age)
Number of subjects: 222